The updated guideline on dyslipidaemia is in concordance with European guidelines (2019). Management of dyslipidaemias aims to reduce the risk of atherosclerotic diseases, determined by cardiovascular risk assessment. Therapeutic targets for plasma LDL cholesterol range from concentrations < 1.4 to < 1.8 mmol/l (persons at very high or high risk), and from < 2.6 mmol/l to < 3.0 mmol/l (moderate or low risk). Changes in lifestyle (diet, physical activity and nonsmoking) are the cornerstones. Drugs, mainly statins, ezetimibe, PCSK9 inhibitors, and in some cases fibrates or resins are initiated as appropriate to reach the targets.
Timo Strandberg (Chair)